Monday, June 3, 2013

• Halozyme's Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic CancerPR Newswire( (Mon, Jun 3)

Thursday, May 23, 2013

• Halozyme Therapeutics Names David A. Ramsay Chief Financial OfficerPR Newswire( (Thu, May 23)

Tuesday, May 21, 2013

• Baxter Receives Marketing Authorization for HyQvia in European UnionBusiness Wire( (Tue, May 21)

Wednesday, May 15, 2013

• Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual MeetingPR Newswire( (Wed, May 15)

Wednesday, May 8, 2013

• Halozyme Reports First Quarter 2013 Financial ResultsPR Newswire( (Wed, May 8)

Tuesday, May 7, 2013

• Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care ConferencePR Newswire( (Tue, May 7)

Wednesday, May 1, 2013

• Halozyme to Host First Quarter 2013 Financial Results Conference CallPR Newswire( (Wed, May 1)

Tuesday, April 23, 2013

• Halozyme Initiates Randomized Phase 2 Trial of PEGPH20 in Pancreatic CancerPR Newswire( (Tue, Apr 23)

Thursday, March 28, 2013

• Halozyme Therapeutics Names Matt Posard to Board of DirectorsPR Newswire( (Thu, Mar 28)

Friday, March 22, 2013

• Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European UnionPR Newswire( (Fri, Mar 22)

Monday, March 11, 2013

• New Programs Designed to Speed Up Approval Process a Key Factor in Biotech Industry's Growth in 2012Marketwired( (Mon, Mar 11)